The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways - Millan, M J; Gobert, A; Lejeune, F (J Pharmacol Exp Ther, 2003)
et al.